Spravato vs Ketamine: Understanding the Critical Differences in Treatment, Cost, and Results
If you have been researching advanced options for treatment resistant depression, you have almost certainly encountered both names. Spravato and ketamine are often discussed in the same breath, and for good reason: they share a chemical family and they both act on the glutamate system in ways that traditional antidepressants do not. But they are not the same thing, and the differences matter. The choice between them can affect everything from your out of pocket cost to your safety profile to the durability of your recovery.
When patients ask us about Spravato vs Ketamine, our job is not to push one over the other. It is to explain, in plain language, what each option actually involves, what the science says, what insurance will and will not cover, and which choice makes the most sense for the individual sitting in front of us. At Serenada Mental Health in Georgetown and Waco, Texas, we offer Spravato treatment and work alongside patients navigating every option on the table. This guide is written for anyone trying to make sense of the conversation. We will walk through the science, the cost, the results, and the practical realities of each option so you can make an informed decision with your clinician.
Spravato vs Ketamine: What Are They, Really?
Ketamine has been used as an anesthetic in the United States since the 1970s. It is on the World Health Organization's List of Essential Medicines and has a long safety record in surgical and emergency settings. In the early 2000s, researchers began studying ketamine's effects on mood, and the results were striking: low dose ketamine infusions produced rapid antidepressant effects in many patients who had not responded to anything else. This discovery opened the door to a new era in psychiatry, but it also created a problem. Generic ketamine was never FDA approved for depression. Clinics began offering it off label, and a patchwork of protocols, prices, and quality standards emerged.
Spravato, the brand name for esketamine, was developed specifically to address this gap. Esketamine is the S enantiomer of ketamine, meaning it is one of the two mirror image molecules that make up the original racemic ketamine compound. In 2019, the FDA approved esketamine nasal spray for adults with treatment resistant depression, defined as having tried two or more antidepressants at adequate dose and duration without meaningful relief. In 2020, the FDA expanded the approval to include major depressive disorder with acute suicidal ideation or behavior. Spravato is the first and only FDA approved ketamine derived treatment for depression. That distinction shapes everything that follows.
The Science: How Each Works in the Brain
Both Spravato and ketamine act on the NMDA receptor, which is part of the brain's glutamate system. Glutamate is the most abundant excitatory neurotransmitter in the brain, and growing evidence suggests that dysregulation in this system plays a central role in depression. By blocking NMDA receptors, both drugs trigger a cascade that increases the release of brain derived neurotrophic factor, or BDNF, and stimulates the growth of new synaptic connections. In plain language: both Spravato and ketamine help the brain rewire itself, which is why they can produce improvements that traditional antidepressants cannot.
The differences emerge in the details. Because esketamine contains only one of ketamine's two enantiomers, it is more potent at the NMDA receptor and may produce a different side effect profile than racemic ketamine. Some researchers believe the S enantiomer accounts for most of ketamine's antidepressant effects, while the R enantiomer may contribute more to its dissociative and psychotomimetic effects. The clinical implication is that Spravato may deliver comparable antidepressant benefit with a somewhat more predictable experience. That said, head to head trials comparing the two directly remain limited, and individual response varies. What we can say with confidence is that both options produce rapid antidepressant effects through the same fundamental mechanism, and both are far faster than the four to six weeks typically required for SSRIs to take effect.
Spravato vs Ketamine: The Comparison Table
Before we go deeper into each dimension, here is a side by side summary of the most important differences between Spravato and generic ketamine therapy. The table below is a quick reference; we expand on each row in the sections that follow:
| Feature | Spravato (Esketamine) | Generic Ketamine |
|---|---|---|
| Form | FDA approved nasal spray (esketamine) | IV infusion, intranasal, sublingual, or oral (off label) |
| FDA Approval | Yes, for TRD and MDD with suicidal ideation | No, used off label for mood disorders |
| Active Molecule | Esketamine (S enantiomer of ketamine) | Racemic ketamine (mixture of R and S enantiomers) |
| Administration Setting | REMS certified clinic under supervision | Outpatient infusion center or clinic |
| Session Length | About two hours with observation | 40 minutes to 1 hour plus recovery |
| Insurance Coverage | Often covered by major plans including Medicare | Rarely covered; usually self pay |
| Time to Effect | Hours to days after first dose | Hours after first infusion |
| Maintenance Phase | Every two weeks to monthly after induction | Varies; often monthly infusions |
Treatment Experience: What Each Protocol Actually Looks Like
The treatment experience differs significantly between the two options. Spravato is administered as a self delivered nasal spray in a REMS certified clinic under the supervision of a healthcare provider. The REMS, or Risk Evaluation and Mitigation Strategy, is an FDA required safety program that ensures the medication is only dispensed in qualified settings. Each session lasts about two hours from intake to discharge, with blood pressure and mood monitoring throughout. Patients remain awake and responsive, and the treatment rooms at Serenada Mental Health are designed to be quiet, private, and comfortable.
To understand exactly what a session involves, our guide to what actually happens during a Spravato session walks through every step. The standard protocol begins with twice weekly sessions for the first four weeks, transitions to weekly sessions for weeks five through eight, and then moves to a maintenance phase with sessions every two weeks or monthly depending on response. Intravenous ketamine therapy, by contrast, typically involves 40 to 60 minute infusions in an outpatient clinic, often delivered as a series of six infusions over two to three weeks. Some patients find IV ketamine's intensity more comforting because they can feel the medication entering their system; others find the nasal spray format of Spravato less intimidating. There is no universally better experience. There is only the experience that fits you and your clinician's plan.
Cost and Insurance: Where the Real Difference Shows Up
For most patients, this is the section that matters most. Ketamine infusion cost varies widely, but patients can generally expect to pay between $400 and $800 per infusion out of pocket. A standard induction series of six infusions often totals $3,000 to $5,000, and ongoing maintenance infusions can add hundreds or thousands of dollars per year. Because generic ketamine is not FDA approved for depression, insurance companies rarely cover it. This means ketamine therapy is, for the vast majority of patients, a cash pay expense.
Spravato is in a different category entirely. Because it is FDA approved, Spravato cost with insurance is often far more manageable. Major commercial plans, including Blue Cross Blue Shield, Aetna, Cigna, and United Healthcare, frequently cover Spravato for patients who meet clinical criteria. Medicare covers Spravato, and TriWest and TriCare coverage makes it accessible to many veterans and military families in Central Texas. Even when copays and deductibles apply, the annual cost of Spravato treatment is often a fraction of what patients would pay out of pocket for a comparable course of generic ketamine infusions. At Serenada Mental Health, our team handles insurance verification and prior authorization as part of our intake process, so you know your financial responsibility before treatment begins.
Results: What Does the Evidence Say?
Both Spravato and ketamine have demonstrated rapid antidepressant effects, but the evidence base is not identical. Spravato's FDA approval rested on multiple phase 3 clinical trials involving thousands of patients. Pooled data from those trials suggests response rates around 60 percent and remission rates near 52 percent for patients with treatment resistant depression. The trials also established dosing protocols, safety monitoring standards, and a structured maintenance phase designed to sustain remission over time.
Generic ketamine's evidence base for depression is substantial but more fragmented. Numerous studies and meta analyses have shown rapid antidepressant effects, often within hours of the first infusion, with response rates ranging from 50 to 70 percent across studies. However, without FDA approval there is no standardized protocol for dosing, frequency, or maintenance. Different clinics use different concentrations, intervals, and follow up schedules. This variability makes it harder to compare outcomes across settings and harder for patients to know what to expect. For a deeper look at how these options fit within the broader landscape of advanced care, see our guide to advanced treatment options for depression. The practical takeaway is this: both Spravato and ketamine can work. Spravato's advantage is not necessarily superior efficacy, but superior standardization. The protocol is well defined, the safety framework is regulated, and the long term maintenance strategy is built into the FDA label.
Safety, Monitoring, and the REMS Program
Both Spravato and ketamine can produce transient side effects during and shortly after administration. The most commonly reported include dissociation, dizziness, sedation, nausea, and brief increases in blood pressure. These effects typically resolve within an hour or two of dosing, which is why both treatments require clinical monitoring. The REMS program that governs Spravato formalizes this requirement. Patients cannot take Spravato home; every dose must be administered and monitored in a qualified healthcare setting, and patients must be observed for at least two hours afterward.
This might sound restrictive, but the REMS program exists for good reason. It ensures that every dose is delivered in a setting equipped to handle any adverse event, that prescribers and pharmacies are properly certified, and that the medication is not diverted or misused. At Serenada Mental Health, we operate under REMS certification at both our Georgetown and Waco clinics, with trained staff present throughout every session. Generic ketamine, when delivered as an IV infusion in a reputable clinic, follows similar monitoring standards out of clinical necessity, even though the REMS framework does not formally apply. The important question for any patient is not which medication has fewer side effects on paper, but which clinic has the systems, staff, and culture to keep you safe while you receive it.
Spravato vs Ketamine: Which Is Right for You?
There is no universal answer to the question of Spravato versus ketamine. The right choice depends on your diagnosis, your insurance, your budget, your comfort with each administration format, and your clinician's assessment of which option best fits your clinical picture. That said, certain patterns tend to hold true.
Spravato may be the better fit if you have a confirmed diagnosis of treatment resistant depression or major depressive disorder with acute suicidal ideation, if you have insurance coverage that includes the medication, and if you prefer the structure of an FDA approved protocol with a defined maintenance phase. Generic ketamine may be worth considering if you do not meet Spravato's FDA approved criteria but still struggle with mood symptoms that have not responded to standard treatments, if you are willing and able to pay out of pocket, and if you live near a reputable infusion clinic. Some patients also explore sublingual ketamine, a compounded formulation that dissolves under the tongue and can be used at home under prescriber guidance. Each option has tradeoffs, and the only way to know which is right for you is a thorough evaluation with a psychiatric provider experienced in interventional psychiatry.
Accessing Spravato Treatment in Central Texas
For adults in Central Texas, accessing FDA approved esketamine therapy has historically meant traveling to Austin, Houston, or Dallas. That is no longer the case. Serenada Mental Health offers Spravato treatment at both our Georgetown and Waco clinics, bringing interventional psychiatry closer to home for residents across the region. Whether you live in Georgetown, Waco, Round Rock, Temple, Belton, or the rural communities in between, the drive to a qualified provider is now shorter than it has ever been.
You can learn more about our protocol and what to expect on our Spravato treatment service page. For patients whose schedules or locations make regular in person visits challenging, our telehealth psychiatry in Texas offering extends the integrative side of care into the home. While the Spravato doses themselves must be administered in person under clinical supervision, much of the surrounding care, including psychiatric follow up, medication management, and much of the psychotherapy, can be delivered securely by video. This hybrid model makes the full treatment course more accessible for working adults, parents, and patients in rural areas.
Take the Next Step With Confidence
The conversation about Spravato vs Ketamine is not really about which drug is better. It is about which option fits your life, your budget, and your clinical needs. Spravato offers the structure of an FDA approved protocol, broad insurance coverage, and a standardized maintenance phase. Generic ketamine offers flexibility and an alternative for patients who do not meet Spravato's criteria. Both have a place in modern depression care, and the right choice almost always emerges from a careful conversation with a qualified psychiatric provider. At Serenada Mental Health, our role is to walk through that conversation with you, not to push a single answer.
If you have been living with depression that has not responded to standard treatments, you do not have to keep waiting for things to change on their own. Spravato treatment is available close to home, delivered by a team that practices integrative, trauma informed, culturally sensitive psychiatry. Where healing begins with understanding, and where the right answer is the one that fits you.
Call us at (512) 612-9441 or click Book Now to schedule a comprehensive consultation at our Georgetown or Waco clinic. The clarity you have been looking for starts with a single conversation, and we would be honored to have it with you.